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A b s t r a c t  
The aim of the present investigation was to prepare bilayer floating tablets of metoprolol tartrate 
using the combination of superdisintigrants, HPMC K grade polymers and natural polymers like 
xanthan gum and guar gum by direct compression method. Bilayer floating tablets were prepared 
using optimized immediate release layer and floating layer as sustained release layer. The physico-
chemical characteristics of the prepared tablets were evaluated and found to be satisfactory. All the 
prepared batches showed in vitro buoyancy. It was observed that the tablets remained buoyant for 
more than 12 h.  Formulation F7 was selected as best formulation based on the in vitro 
characteristics and used in vivo radiographic studies by adding barium sulphate. These studies 
revealed that the tablets remained in the stomach for 210μ5.4 min (n=3) in fasting human 
volunteers. Based on the in vivo performance in healthy subjects, the developed bilayer floating 
tablets showed superior bioavailability than the marketed tablets, the drug release was up to 12 h in 
controlled manner. The systemic availability of the best formulation was high after administration to 
obtain immediate action due to the immediate release layer, from sustained release layer the drug 
was released in controlled manner. It can be concluded that the best formulation F7 by choosing 
biphasic drug release pattern in a single dosage form could improve patient compliance and ensure 
better disease management. 
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Introduction 
Oral administration is the most versatile, convenient and commonly 
employed route of drug delivery for systemic action. Indeed, for 
controlled release system, oral route has gained more attention 
and success because gastro intestinal physiology offers more 
flexibility in dosage form design than other routes [1]. The benefits 
of long term delivery technology have not been fully realized for 
dosage forms designed for oral administration [2]. Development of 
oral controlled release systems has been a challenge to 
formulation scientists because of the difficulty in localizing the 
system in target areas of the gastrointestinal tract [3].  
Gastroretentive drug delivery system is an approach to prolong the 
gastric residence time, thereby targeting site-specific drug release 
in the upper gastrointestinal tract (GIT) for local or systemic effects. 
These dosage forms can remain in the gastric region for longer 
period and hence significantly prolong the gastric retention time of 
the drugs [4]. Floating drug delivery systems are low-density 
systems that have sufficiently to float over the gastric contents and 
remain buoyant in the stomach without affecting the gastric 
emptying rate for a prolonged period of time. This results in an 
increased gastric retention time and a better control of the 
fluctuations in plasma drug concentration [5]. Bilayer tableting 
technology has been specially developed to provide two different 
release rates or biphasic release of a drug from a single dosage 
form [6].   
Metoprolol tartrate is a selective β
1
-blocking drug used for the 
management of moderate to severe essential hypertension [7]. 
Because of its relative short plasma half-life, patients are routinely 
asked to take metoprolol tartrate in divided daily doses, once every 
6 to 8h. Such frequent drug administration may reduce patient 
compliance and therapeutic efficacy [8]. The multilayer tablet 
concept has been long utilized to develop sustained release 
formulations such a tablet has a fast releasing layer and may 
contain bi or tri layers to sustain the drug release [9]. The present 
study aims at formulating bilayer floating tablets of metoprolol 
tartrate with immediate release layer using super disintegrants like 
crospovidone, croscarmellose sodium and sodium starch glycolate 
in combination and alone, and a sustained release layer using 
hydroxy propyl methyl cellulose K-4M, K-15M, K-100M, Pvpk30 
and sodium carboxy methyl cellulose polymers. The prepared 
tablets were evaluated for their compatibility studies, physico-
chemical characteristics, in vivo radiographic and in vivo 
bioavailability studies. 
Materials and Methods 
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Materials 
Betaloc 100mg conventional tablet was purchased from 
AstraZeneca. Metoprolol tartrate was a generous gift from Dr. 
ReddyÊs Laboratories Limited, (Hyderabad, India). Hydroxy propyl 
methyl cellulose K4M, K15M and K100M were obtained from 
Colorcon Asia Private Limited, India. Xanthan gum, guar gum, 
crospovidone, croscarmellose sodium, sodium starch glycolate and 
PVP-K30 were gifted from MSN Labs Ltd, Hyderabad.  All other 
chemicals used were of analytical grade. 
Preparation of bilayer floating tablets 
Formulation of immediate release (IR) layer 
Eight formulation batches with different super disintegrants were 
made in order to achieve desired disintegration time and drug 
release. The composition of metoprolol tartrate immediate release 
tablets was shown in Table 1. 
 
Table 1. Composition of metoprolol tartrate immediate release layer  
Ingredients (mg) IR1 IR2 IR3 IR4 IR5 IR6 IR7 IR8 
Metoprolol tartrate 25 25 25 25 25 25 25 25 
PVP K30     4 6 4 5 4 4 4 6 
Crospovidone   10  15 - - - 12.5 -   10 
Croscarmellose sodium - - 15 - - - 10 - 
 SSG - - - 10 15 - - 10 
MCC 108 - - - 103 - - - 
Lactose - 101 103 107 - - - 96 
DCP - - - - - 105.5 108 - 
Mg. Stearate 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Talc 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Total wt. 150 150 150 150 150 150 150 150 
 
Formulation of floating sustained release (SR) tablets 
Required quantity of metoprolol tartrate and other polymers was 
weighed and passed through sieve with mesh #40 and were mixed 
homogeneously in a poly-bag for about 5-10 min. The powder 
mass was passed through mesh #14. Finally the powder was 
lubricated with magnesium stearate and talc.  
Formulation of floating bilayer tablets 
The powder of floating sustained release layer was poured in the 
die cavity and the powder was compressed. After the compression, 
the upper punch was then lifted and the immediate release layer 
powder was placed in the die, containing initially compressed 
sustained release layer and compressed to form bilayer tablet. The 
composition of different formulations of metoprolol tartrate floating 
bilayer tablets are depicted in the Table 2. 
Table 2. Composition of metoprolol tartrate floating bilayer tablets 
Ingredients (mg) F1 F2 F3 F4 F5 F6 F7 
IR8 150 150 150 150 150 150 150 
Metoprolol tartrate 75 75 75 75 75 75 75 
HPMC K4M 130 - 130 - - - - 
HPMC K15M - 130 - - - - - 
HPMC K100M - - - 130 130 130 150 
Xanthan gum 10.5 35 17.5 10.5 10.5 35 17.5 
Guar gum 10.5 - 17.5 10.5 10.5 3.5 17.5 
NaHCO3 60 60 60 60 60 60 60 
Citric acid - - - - - - 10 
SCMC 20 20 20 20 20 20 10 
Lactose 24 10 25 39 14.5 - 5 
MCC - - - - - 21.5 - 
Mg.Sterate 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
Talc 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
Total weight 500 500 500 500 500 500 500 
Kumari et al. International Journal of Drug Delivery 6 (1) 14-23 [2014] 
 
PAGE | 16 |
 
 
Evaluation of metoprolol tartrate bilayer floating 
tablets10  
Thickness 
The thickness of the prepared tablets was tested using vernier 
calipers. The test was done in triplicate and average thickness was 
determined. 
Hardness 
Hardness of prepared tablets was determined using Monsanto 
hardness tester and measured in terms of kg/cm2. 
Weight variation 
Formulated tablets were tested for weight uniformity. Twenty 
randomly taken tablets were weighed together and the average 
weight was determined. Each tablet was then weighed individually 
and deviation from average weight was calculated. The percent 
weight variation was calculated by using the following formula.[10]. 
 
                                         Average weight - Individual weight 
% Weight variation =   ------------------------------------------------- 
                                                       Average weight 
Friability 
The Roche friability test apparatus (Electrolab) was used to 
determine the friability of the tablets. Twenty pre-weighed tablets 
were placed in the apparatus operated for 4 min at a speed of 25 
rpm. The tablets were removed from the friabilator, de-dusted and 
reweighed. The percentage friability was calculated according to 
the following formula [11].  
                                         Initial weight - Final weight 
                %Friability =   ------------------------------------    X 100 
                                             Initial weight 
Drug content uniformity test 
Ten tablets for each batch was weighed and powdered. A quantity 
of powder equivalent to 100mg of drug was taken into 100ml 
volumetric flask. The amount of drug present in the powder was 
determined by dissolving the powder mixture in 0.1N HCl and 
measure the drug content spectrophotometrically at 275nm using 
UV/Visible spectrophotometer (Shimadzu 1800) against 0.1N HCl 
blank [12].  
Swelling studies 
The extent of swelling was measured in terms of % of weight 
gained by the tablet. One tablet from each formulation was 
weighed and kept in petri dish containing 50 ml of 0.1N HCl buffer 
solution. At the end of specified time intervals, tablets were 
withdrawn from petri dish and excess buffer blotted with tissue 
paper and weighed13. The % of weight gained by the tablet was 
calculated by using the following formula: 
Swelling Index (%) = Mt-M0/M0 X 100.  
Buoyancy lag time determination & total floating time 
The in vitro buoyancy was determined by the floating lag time. The 
tablet was placed in a 100 ml beaker containing 0.1N HCl. The 
time required for the tablet to rise to the surface for floating was 
determined as the buoyancy lag time and further total floating time 
of all tablets was determined by visual observation [14]. 
In vitro disintegration time of immediate release layer 
The disintegration time for all immediate release formulations was 
carried out using tablet disintegration test apparatus (Electrolab). 
Six tablets were placed individually in each tube of disintegration 
test apparatus and discs were placed. The medium, water was 
maintained at a temperature of 37μ2 0C and time taken for the 
entire tablet to disintegrate completely was noted [15]. 
In vitro dissolution studies 
In vitro drug release studies for the prepared immediate release 
layer and bilayer floating tablets were conducted for a period of 10 
min and 12 h respectively using USP XXIV type-II (Paddle) 
dissolution apparatus (Electrolab) at 37μ0.5 0C at 50 rpm using 
900 ml of 0.1N HCl as dissolution medium. At predetermined 
interval of time, 5 ml of sample was withdrawn and replaced with 
fresh dissolution medium. The samples were filtered, suitably 
diluted and absorbance was analyzed using UV/Visible 
spectrophotometer (Shimadzu 1800) at 275 nm [16]. 
Kinetic modelling of drug release  
The dissolution profiles of all the batches were fitted to zero order, 
first order, Higuchi16 and Korsmeyer-Peppas equations [17]. 
Drug excipient compatibility studies 
Differential scanning calorimetry (DSC) 
Differential scanning calorimetry (DSC) studies were carried out 
using DSC 60, having TA60 software, Shimadzu, Japan. DSC 
scans of about 5 mg using an automatic thermal analyzer system 
preformed accurately weighed metoprolol tartrate and tablet 
containing the same amount of the drug. Sealed and perforated 
aluminium pans were used in the experiments for all the samples. 
Temperature calibrations were performed using indium as 
standard. An empty pan sealed in the same way as the sample 
was used as a reference. The entire samples were run at a 
scanning rate of 100C/min from 50-300 0C [18]. 
Stability studies 
The stability studies were carried out as per ICH guidelines. The 
best formulation F7 was subjected to accelerated stability test by 
storing at 40μ2ÀC/75μ5% relative humidity in an accelerated 
stability chamber (Remi, Mumbai). After specified period of time (1, 
2 & 3 months) samples were withdrawn and floating lag time, total 
floating time and in vitro dissolution studies were conducted [19].  
In vivo radiographic studies 
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The study protocol for radiographic studies was approved by the 
Institutional Human Ethics Committee (IHEC), Vaagdevi College of 
Pharmacy, Hanamkonda, Warangal, India. To make the best 
achieved X-ray opaque, 100 mg of the drug was replaced with 
barium sulphate and all other ingredients were kept constant. The 
study was conducted on three healthy male volunteers, each 
weighing between 55-70 kg and in the age group of 25μ2 years. 
The tablets prepared for radiography (F7) were administered orally 
with a glass of water. During the study, the subjects were not 
allowed to eat but water was available ad libitum. After ingestion of 
the tablets, the volunteers were exposed to X-ray photography in 
the abdominal region at 0.5, 1.5, 3, 4 and 5 h after administration. 
The mean gastric residence time was calculated.  
In vivo bioavailability studies 
Six healthy male subjects were participated in this study (22-30 
years, weighing 55-75 kg). Informed and signed consent and 
approval of the Human Ethical Committee were obtained. 
Metoprolol tartrate (F7) and reference product (Betaloc 100mg) 
was administered with a glass of water. The volunteers continued 
fasting for 4h, after which standard meal was provided. About 5 ml 
of blood was withdrawn at different time intervals such as 0, 0.5, 1, 
2, 4, 6, 8, 10, 12 and 24 h. Blood samples were collected from 
each subjectÊs forearm vein using a sterile disposable needle and 
syrange into sterile glass centrifuge tubes containing 1 ml of 4% 
anhydrous sodium citrate solution. The samples were centrifuged 
immediately at 4000 rpm and the plasma was stored in light-
protected container at -20 0C till analysis. The concentration of 
metoprolol tartrate from plasma was measured by using reversed 
phase HPLC. The chromatographic system consisted of a C18 
column (Phenomenex) with a 5 øm particle size. The mobile phase 
used was phosphate buffer (adjusted to pH 3.5 with phosphoric 
acid) and acetonitrile (32:68). Plasma samples (250 øl) were 
transferred into a test tube to which internal standard (Pinacidil 
monohydrate 50øl) and 1 mL of acetic acid was added and 
vortexed for 3 min. To this, 1mL of chloroform was added and 
vortexed. The samples were centrifuged at 10,000 rpm for 10 min. 
The organic phase was transferred into another test tube and the 
solvent was evaporated to dryness. The residue was redissolved in 
200 øL of mobile phase, of which 20 øL of the supernatant was 
injected for analysis [20].  
Pharmacokinetic analysis   
The pharmacokinetic parameters employed to evaluate were 
maximum plasma concentration (Cmax), time to attain Cmax i.e., 
Tmax and t ó values, area under plasma concentrationătime curve 
from zero to the last sampling time (AUC0-t), area under plasma 
concentrationătime curve from zero to infinity (AUC0-¥) and mean 
residence time (MRT). AUC0-t was calculated by the linear 
trapezoidal rule and AUC0-¥ from the following formula. 
AUC0-¥ = AUC0-t + Ct / KE 
Results & Discussion 
Physico-chemical parameters of metoprolol tartrate 
bilayer floating tablets 
The prepared tablets were evaluated for different physico-chemical 
properties and the results are found to be within the 
pharmacopoeial limits, which depicted in Table 3.  
 
 
Table 3. Physico-chemical parameters of metoprolol tartrate bilayer floating tablets 
Formulation code 
Weight 
variation (mg) 
(n = 20) 
 
Hardness 
(kg/cm2) (n = 
3) 
 
Thickness (mm) 
(n = 3) 
 
Friability (%) 
(n = 20) 
 
Content uniformity (%) 
(n = 10) 
 
F1 500μ0.9 4.9μ0.11 5.02μ0.04 0.42μ0.03 97.34μ0.35 
F2 498μ0.7 4.5μ0.16 5.05μ0.07 0.39μ0.05 96.50μ0.65 
F3 499μ0.4 5.1μ0.14 5.06μ0.09 0.43μ0.02 98.55μ0.50 
F4 501μ0.1 5.0μ0.18 5.10μ0.06 0.42μ0.06 98.85μ0.75 
F5 502μ0.3 5.2μ0.02 5.03μ0.03 0.45μ0.04 98.90μ0.55 
F6 499μ0.7 5.1μ0.13 5.08μ0.02 0.44μ0.01 98.69μ0.45 
F7 501μ0.7 5.1μ0.13 5.10μ0.02 0.42μ0.01 99.19μ0.45 
 
Swelling studies of metoprolol tartrate bilayer floating 
tablets 
The purpose of swelling study is to determine the water uptake 
capability of the polymer. All the formulations were evaluated for 12 
h and the % swelling index of all the formulations at different time 
intervals i.e. from 0 to 12 h were shown in Table 4. From the  
 
results it was concluded that the increased concentration of HPMC 
in the formulations increases the swelling indices. The best 
formulation F7 prepared by using HPMC K 100M showed highest 
swelling indices.  
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Table 4. Swelling index of metoprolol tartrate bilayer floating tablets 
Time (h) 
Swelling Index (%)*
 
F1 F2 F3 F4 F5 F6 F7
0 
 
0 
 
 0 0 0 0 
 
0 0 
1  
43.32 
 
46.89 41.34 56.32 58.12 
 
57.36 60.33 
2  64.52 
 
71.52 62.12 82.56 84.52 80.52 85.12 
3 74.08 80.08 73.09 95.03 94.08 96.07 99.07
4 86.61 91.61 84.66 113.31 112.61 110.41 110.61
6 98.12 112.12 96.14 125.78 129.12 128.17 132.14
8 108.31 125.32 104.12 140.12 145.32 144.52 153.32
10 124.71 140.46 122.75 155.61 162.71 160.71 168.82
12 146.30 164.60 141.29 181.28 184.29 182.24 191.23
*Mean μ SD (n=3) 
 
Buoyancy lag time determination & total floating time  
All the formulations had buoyancy lag time in the range of 23 to 78 
sec. F1-F6 formulations shows buoyancy lag period of 25-78 sec. 
The best formulation F7 lag time was found to be 23 sec. The total 
floating time was found to be more than 12 h, which indicates a 
stable gel layer formation by all polymers and that NaHCO3 
remains for a longer time.  
In vitro disintegration time of immediate release layer  
In the present investigation 8 formulations were made with different 
superdisintegrants like crospovidone, croscarmellose sodium and 
SSG. The optimized formulation (IR8) prepared by using 
combination of superdisintegrants cross povidone and sodium 
starch glycolate disintegrated in lesser time i.e 39 sec compare 
with other formulations.  
In vitro release profile of immediate release tablets:  
The immediate release tablets of 8 formulations (IR1-IR8) prepared 
by using different superdisintegrants (Table 1) alone and in 
combination showed % drug release of about 98.08, 99.5, 98.4, 
100.7 and 98.5 for IR1, IR2, IR4, IR5 and IR6 respectively at the 
end of 15 min. The formulations IR3 and IR7 showed the drug 
release of 100.8 and 99.55 at 20min and the drug release from the 
optimized formulation IR8 was found to be 99.5 at the end of 10 
min. Among all the formulations IR8 consisting of crospovidone 
and sodium starch glycolate in combination considered as 
optimized formulation. IR8 was further used in the preparation of all 
bilayer floating tablets.  
In vitro release profile of metoprolol tartrate bilayer 
floating tablets  
All the sustained release formulations (F1-F7) are prepared with 
different grades of HPMC, natural polymers like xanthan gum, guar 
gum and sodium CMC showed drug release between 97.85 to 
100% at the end of 10-12 h. Approximately 40% of the drug was 
released from the best formulation (F7) in the first hour as loading 
dose to attain quick action from the immediate layer. Formulation 
F7 containing the polymer HPMC K100M in higher concentration, 
results in strong gel strength that retards the drug release upto 12 
h. The in vitro drug release profile of conventional dosage form 
(Betoloc 100mg) was found to be 98.40 after 30 min. 
 
Figure 1. Comparative % drug release profiles of metoprolol tartrate bilayer floating tablets 
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Kinetic modelling of drug release: 
To explore the mechanism of drug release from bilayer floating 
tablets, various kinetic models like zero order, first order, Higuchi 
and Korsmeyer-Peppas equations were applied to the different 
formulations. The release kinetics of best formulation (F7) was 
shown in Table 5. From the data it was concluded that the 
formulation F7 followed first order kinetics. When the drug release 
data was fitted to Higuchi equation, linear plots were obtained with 
high correlation coefficient values. The drug release was 
proportional to square root of time indicating that the drug release 
was diffusion controlled.    
  
Table 5. Release kinetics of best formulation (F7) of metoprolol tartrate bilayer floating tablets  
Zero Order First order Higuchi Korsmeyer-Peppas 
r2  ko (h-1) r2 k1(h-1) r2 kH (h-1/2) r2 n value 
0.905 5.62 0.921 -0.077 0.955 24.49 0.972 0.336 
 
Drug excipient compatibility studies: 
DSC studies: 
 
Figure 2. DSC thermogram of metoprolol tartrate pure drug 
 
Figure 3. DSC thermogram of metoprolol tartrate best formulation (F7) 
 
 
The DSC thermograms of the pure metoprolol tartrate (Figure 2) 
and best formulation (F7) (Figure 3) showed endothermic peaks at 
122.4 and 125.6 0C respectively. It indicates that there is no 
interaction takes place between drug and other excipients used in 
the formulation. 
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Stability studies 
The stability of best formulation F7 was tested at 40μ2 ÀC/75μ5% 
relative humidity for 3 months. There was no significant change in 
floating lag time, total floating time and also in vitro drug release 
profile, where results are summarized in Table 6.  
 
Table 6. Stability data of best formulation (F7)  
Retest time for F7 
Floating lag time(sec)* Total floating time (h)* In vitro drug release profile 
(%)* 
0 days 
23μ1.5 >12 h
98.99 
30 days 
25μ2.0 >12 h
96.24 
60 days 
26μ1.0 >12 h
95.35 
90 days 
28μ2.5 >12 h
94.35 
*Mean μ SD (n=3) 
 
Intragastric behaviour of bilayer floating tablets 
The radiographic images were taken at different periods post-
administration of the barium sulfate-loaded tablet in three human 
volunteers (Figure 4. A-D). It is clear that the tablet appears more 
or less at the same position for the initial 3 h. This could be related 
to its floating ability. Later on, the tablet was slightly moved 
downwards, yet, remained within the stomach till the end of 4 h. 
The mean gastric retention period was found to be 210μ5.4 min (n 
= 3). The increased gastric residence time favours increase in the 
bioavailability of drugs. 
 
 
           A)  30min                                                      B) 90 min 
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             C) 3 h                                                                     D) 4 h 
 
Figure 4. Radiographic images showing the presence of a BaSO4 loaded bilayer floating    
tablet (F7) in the stomach at a different time periods. 
 
 
Bioavailability studies 
 
 
Figure 5: Comparative in vivo bioavailability profiles of the test formulation F7 and reference product (Betaloc).  
 
Table 7. Pharmacokinetic parameters of test (F7) and marketed reference (Betaloc) formulation (n = 6) 
 
Pharmacokinetic 
Parameters 
Test formulation F7 
Mean μ SD 
Reference product 
Mean μ SD 
Cmax (øg/ml) 1094 μ 201 698μ124
Tmax (h-1) 6.3 μ1.2 1.5μ0 
AUC 0-t (øg h/ml) 4010 μ 689 1458μ357 
AUC 0ă¥ (øg h/ml) 4673 μ 776 2031μ482 
t 1/2 (h) 4.23 μ 0.44 0.50μ1.25 
MRT(h) 10.33 μ 0.86 3.75μ0.37 
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Pharmacokinetic studies were carried out in healthy human 
volunteers for test formulation and reference drug and the results 
were depicted in Table 7. The comparison of plasma drug 
concentration of test formulation F7 and reference product was 
shown in Figure 5. Cmax and Tmax for test formulation and 
reference formulations was found to be 1094 μ 201 øg/ml, 6.3 μ 2 h 
and 698 μ 124 øg/ml, 1.5 μ 0 h respectively. In order to estimate 
the amount of drug absorbed from the test formulation, the relative 
bioavailability was calculated from the AUC 0ă¥ of the reference and 
test formulation (2031 μ 482 øg h/ml and 4673 μ 776 øg h/ml). The 
AUC 0-t of reference and test formulation was found to be 
1458μ357 øg h/ml and 4010 μ 689 øg h/ml. These results indicated 
that the bioavailability of the test formulation was increased 
significantly compare with reference one. The t1/2 for test 
formulation and conventional product were 4.23 μ 0.44 h and 
0.50μ1.25 h, respectively. The MRT for test formulation was 
significantly longer than the reference (10.33 μ 0.86 h and 
3.75μ0.37).  
Conclusion 
In the present investigation, several formulations were prepared by 
using different polymers for immediate layer and sustained layer 
separately. Based on the evaluation parameters for immediate 
layer, IR8 was found to be optimized formulation upon its 
disintegration time i.e., 39 sec. For Sustained release tablet, F7 
was decided as best formulation, because the lag time, buoyancy 
period and in vitro drug release was better than other formulations.  
The release pattern of bilayer tablet was best fitted to First order 
and Higuchi kinetic model with R2 values of 0.921and 0.955 
respectively. The value of n = 0.336 suggested that the drug is 
released from bilayer sustain dosage form by Fickian diffusion 
mechanism. In vivo radiographic studies revealed that the best 
formulation (F7) remained for 210 μ 5.4 min, which indicated that 
gastric retention time was increased by the floating mechanism 
which was considered desirable for improving the bioavailability of 
the drugs. 
The comparison of in vivo bioavailability studies of test formulation 
and that of a reference formulation in healthy human volunteers 
confirmed that the test formulation increased the oral bioavailability 
with immediate action and later sustained action. Hence we can 
conclude from our study that the metoprolol tartrate bilayered 
floating tablets prepared by using hydrophilic and hydrophobic 
polymers are a promising alternative for the effective management 
of hypertension. 
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